摘要:
Compounds having activity against production of inflammatory cytokines of formula (I)′: A′ is pyrrole; R1′ is aryl or heteroaryl; R2′ is heteroaryl having at least one nitrogen atom; R3′ is (IIa)′, (IIb)′ or (IIc)′: m′ is 1 or 2; one of D′ and E′ is nitrogen and the other is >C(R5′)—, R5′ is hydrogen, Substituent α′ or Substituent β′; B′ is nitrogen-containing 4- to 7-membered heterocyclic; R4′ is 1 to 3 substituents from Substituent α′, Substituent β′ and Substituent γ′; R1′ and R3′ are bonded to two atoms of the pyrrole adjacent to the pyrrole atom bonded to R2′; Substituent α′: hydroxyl, nitro, cyano, halogen, alkoxy, halogeno alkoxy, alkylthio, halogeno alkylthio or —NRa′Rb′; Ra′ and Rb′ are hydrogen, alkyl, alkenyl, alkynyl, aralkyl or alkylsulfonyl, or Ra′ and Rb′ with the nitrogen atom form a heterocyclyl; Substituent β′: alkyl, alkenyl, alkynyl, aralkyl or cycloalkyl; Substituent γ′: oxo, hydroxyimino, alkoxyimino, alkylene, alkylenedioxy, alkylsulfinyl, alkylsulfonyl, aryl, aryloxy, alkylidenyl or aralkylidenyl.
摘要翻译:具有抗式产生式(I)的炎性细胞因子的化合物的化合物:A'是吡咯; R 1是芳基或杂芳基; R 2是具有至少一个氮原子的杂芳基; (IIa)',(IIb)'或(IIc)':m'为1或2; D'和E'之一是氮,另一个是> C(R 5') - ,R 5'是氢,取代基α'或取代基β'; B'是含氮的4-至7-元杂环; R 4'是1至3个取代基α',取代基β'和取代基γ'的取代基; R 1'和R 3'连接到与R 2'连接的吡咯原子相邻的吡咯的两个原子上; 取代基α':羟基,硝基,氰基,卤素,烷氧基,卤代烷氧基,烷硫基,卤代烷硫基或-NR a R b b。 R a,O和R b'是氢,烷基,烯基,炔基,芳烷基或烷基磺酰基,或者R a'和R“ b'与氮原子形成杂环基; 取代基β':烷基,烯基,炔基,芳烷基或环烷基; 取代基γ':氧代,羟基亚氨基,烷氧基亚氨基,亚烷基,亚烷基二氧基,烷基亚磺酰基,烷基磺酰基,芳基,芳氧基,亚烷基或芳烷基。
摘要:
A bicyclic unsaturated tertiary amine compound capable of inhibiting the production of inflammatory cytokines. The compound has the following formula (I): wherein A represents pyrrole or pyrazole, R1 represents an aryl group or a heteroaryl group which may be substituted, R2 represents a heteroaryl group which may be substituted, and R3 represents an indolizine group, or a pharmacologically acceptable salt thereof, a pharmacologically acceptable ester thereof or a pharmacologically acceptable derivative thereof.
摘要:
Compounds having activity against production of an inflammatory cytokine of formula (I)′: A′ is pyrrole; R1′ is phenyl or naphthyl; R2′ is pyridyl or pyrimidinyl; R3′ is (IIa)′, (IIb)′ or (IIc)′: m′ is 1; E′ is nitrogen; D′ is >C(R5′)—, R5′ is hydrogen, Substituent α′ or Substituent β′; B′ is nitrogen-containing 5-membered heterocyclic; R4′ is 1 to 3 substituents from Substituent α′, Substituent β′ and Substituent γ′; R1′ and R3′ are bonded to two atoms of the pyrrole adjacent to the pyrrole atom bonded to R2′; Substituent α′ is hydroxyl, nitro, cyano, halogen, alkoxy, halogeno alkoxy, alkylthio, halogeno alkylthio or —NRa′Rb′; Ra′ and Rb′ are hydrogen, alkyl, alkenyl, alkynyl, aralkyl or alkylsulfonyl, or Ra′ and Rb′ with the nitrogen atom form a heterocyclyl; Substituent β′ is alkyl, alkenyl, alkynyl, aralkyl or cycloalkyl; Substituent γ′ is oxo, hydroxyimino, alkoxyimino, alkylene, alkylenedioxy, alkylsulfinyl, alkylsulfonyl, aryl, aryloxy, alkylidenyl or aralkylidenyl.
摘要翻译:具有抗式产生式(I)的炎性细胞因子的活性化合物的化合物:A'是吡咯; R 1是苯基或萘基; R 2是吡啶基或嘧啶基; (IIa)',(IIb)'或(IIc)':m'为1; E'是氮; D'是> C(R 5') - ,R 5'是氢,取代基α'或取代基β'; B'是含氮5元杂环; R 4'是1至3个取代基α',取代基β'和取代基γ'的取代基; R 1'和R 3'连接到与R 2'连接的吡咯原子相邻的吡咯的两个原子上; 取代基α'是羟基,硝基,氰基,卤素,烷氧基,卤代烷氧基,烷硫基,卤代烷硫基或-NR a R b B。 R a,O和R b'是氢,烷基,烯基,炔基,芳烷基或烷基磺酰基,或者R a'和R“ b'与氮原子形成杂环基; 取代基β'是烷基,烯基,炔基,芳烷基或环烷基; 取代基γ'是氧代,羟基亚氨基,烷氧基亚氨基,亚烷基,亚烷基二氧基,烷基亚磺酰基,烷基磺酰基,芳基,芳氧基,亚烷基或芳亚烷基。
摘要:
A cyclic tertiary amine compound which is capable of inhibiting the production of inflammatory cytoines. The compound having a structure represented by the following formula (I): wherein A represents an optionally substituted trivalent group which is benzene, pyrimidine, pyrrole, pyridine, pyridazine, furan, thiopene, pyrazole, imidazole, isoxazole or isothiazole; R1 represents an aryl or a heteroaryl group, which is unsubstituted or substituted; R2 represents a heteroaryl group which is unsubtituted or substituted; and R3 represents a cyclic tertiary amino group, or a pharmacologically acceptable salt of the compound.
摘要翻译:能够抑制炎性细胞因子产生的环状叔胺化合物。 具有由下式(I)表示的结构的化合物:其中A表示任选取代的三价基团,其为苯,嘧啶,吡咯,吡啶,哒嗪,呋喃,噻吩,吡唑,咪唑,异恶唑或异噻唑; R 1表示未取代或取代的芳基或杂芳基; R 2表示未取代或取代的杂芳基; R 3表示化合物的环状叔氨基或药理学上可接受的盐。
摘要:
Compounds having activity against production of an inflammatory cytokine of formula (I)′: A′ is pyrrole; R1′ is phenyl or naphthyl; R2′ is pyridyl or pyrimidinyl; R3′ is (IIa)′, (IIb)′ or (IIc)′: m′ is 1; E′ is nitrogen; D′ is >C(R5′), R5′ is hydrogen, Substituent α′ or Substituent β′; B′ is nitrogen-containing 5-membered heterocyclic; R4′ is 1 to 3 substituents from Substituent α′, Substituent β′ and Substituent γ′; R1′ and R3′ are bonded to two atoms of the pyrrole adjacent to the pyrrole atom bonded to R2′; Substituent α′ is hydroxyl, nitro, cyano, halogen, alkoxy, halogeno alkoxy, alkylthio, halogeno alkylthio or —NRa′Rb′; Ra′ and Rb′ are hydrogen, alkyl, alkenyl, alkynyl, aralkyl or alkylsulfonyl, or Ra′ and Rb′ with the nitrogen atom form a heterocyclyl; Substituent β′ is alkyl, alkenyl, alkynyl, aralkyl or cycloalkyl; Substituent γ′is oxo, hydroxyimino, alkoxyimino, alkylene, alkylenedioxy, alkylsulfinyl, alkylsulfonyl, aryl, aryloxy, alkylidenyl or aralkylidenyl.
摘要翻译:具有抗式产生式(I)的炎性细胞因子的活性化合物的化合物:A'是吡咯; R 1是苯基或萘基; R 2是吡啶基或嘧啶基; (IIa)',(IIb)'或(IIc)':m'为1; E'是氮; D'是> C(R 5'),R 5'是氢,取代基α'或取代基β'; B'是含氮5元杂环; R 4'是1至3个取代基α',取代基β'和取代基γ'的取代基; R 1'和R 3'连接到与R 2'连接的吡咯原子相邻的吡咯的两个原子上; 取代基α'是羟基,硝基,氰基,卤素,烷氧基,卤代烷氧基,烷硫基,卤代烷硫基或-NR a R b B。 R a,O和R b'是氢,烷基,烯基,炔基,芳烷基或烷基磺酰基,或者R a'和R“ b'与氮原子形成杂环基; 取代基β'是烷基,烯基,炔基,芳烷基或环烷基; 取代基γ'是氧代,羟基亚氨基,烷氧基亚氨基,亚烷基,亚烷基二氧基,烷基亚磺酰基,烷基磺酰基,芳基,芳氧基,亚烷基或芳亚烷基。
摘要:
A compound of formula (I) Wherein X, Y, ring A, ring B, l, m, R1, R2, R4 and R5 are as defined herein, to supress intracellular signal transduction or cell activation induced by endotoxin and to suppress cell responses due to the intracellular signal transduction and cell activation such as an excess generation of inflammatory mediators such as TNF-α, pharmacologically acceptable salts therefor, a preparation method therefor, and a medicament containing the aforementioned substituted cycloalkene derivative as an active ingredient which is superior in prophylaxis and/or treatment of diseases such as sepsis (septic shock, disseminated intravascular coagulation, multiple organ failure and the like), that are associated with intracellular signal transduction or cell activation induced by endotoxin and to cell responses to the intracellular signal transduction and cell activation.
摘要:
A compound of formula (I) Wherein X, Y, ring A, ring B, l, m, R1, R2, R4 and R5 are as defined herein, to supress intracellular signal transduction or cell activation induced by endotoxin and to suppress cell responses due to the intracellular signal transduction and cell activation such as an excess generation of inflammatory mediators such as TNF-α, pharmacologically acceptable salts therefor, a preparation method therefor, and a medicament containing the aforementioned substituted cycloalkene derivative as an active ingredient which is superior in prophylaxis and/or treatment of diseases such as sepsis (septic shock, disseminated intravascular coagulation, multiple organ failure and the like), that are associated with intracellular signal transduction or cell activation induced by endotoxin and to cell responses to the intracellular signal transduction and cell activation.
摘要:
[Object] To provide a substituted cycloalkene derivative having an action to suppress intracellular signal transduction or cell activation induced by endotoxin and to suppress cell responses due to the intracellular signal transduction and cell activation such as an excess generation of inflammatory mediators such as TNF-α, pharmacologically acceptable salts therefor, a medicament containing them as an active ingredient, a preparation method therefor, and a medicament containing the aforementioned substituted cycloalkene derivative as an active ingredient which is superior in prophylaxis and/or treatment of diseases such as sepsis (septic shock, disseminated intravascular coagulation, multiple organ failure and the like), that are associated with intracellular signal transduction or cell activation induced by endotoxin and to cell responses to the intracellular signal transduction and cell activation.[Solution] A compound represented by the general formula (I): {whereinX and Y represent a group in which X and Y together with a carbon atom to which they are bound form ring A (the ring is 3- to 7-membered heterocyclyl ring or 3- to 7-membered cycloalkyl ring), each represents a hydrogen atom, or X and Y together represent a substituent of ring B. l and m, independently from each other, represent an integer of 0 to 3, and l+m is 1 to 3. R1 is an aliphatic hydrocarbon group and the like which may be substituted with a group selected from Substituent group β and Substituent group γ. n represents an integer of 0 to 3. R2 is a C1-C6 alkyl group and the like which may be substituted with a group selected from a hydrogen atom and Substituent group β. R3 is a phenyl group, 5- to 6-membered heteroaryl group and the like which may be substituted with a group selected from Substituent group ε. R5 is a C1-C6 alkyl group and the like which may be substituted with a group selected from a hydrogen atom and Substituent group β. Provided that in the case where R3 is a phenyl group which may be substituted with a group selected from Substituent group ε, X and Y represent a group in which X and Y together with a carbon atom to which they are bound form ring A, or X and Y together represent a substituent of ring B.
摘要:
It is an object of the present invention to provide a substituted propanamide derivative or a pharmacologically acceptable salt thereof that is useful as a prophylactic or therapeutic agent for a bone metabolic disease. The present invention relates to a pharmaceutical composition comprising a compound having General Formula (I) or a pharmacologically acceptable salt thereof as an active ingredient: [wherein, R1 represents a C6-C10 aryl group that may be substituted by a group selected from Substituent Group α, for example; R2 represents a C6-C10 aryl group that may be substituted by a group selected from Substituent Group α, for example; and X represents a hydroxyl group or a C1-C6 alkoxy group, for example].
摘要:
A pharmaceutical composition comprising a compound having Formula (I) or a pharmacologically acceptable salt thereof as an active ingredient: [wherein, R1 is, for example, a C6-C10 aryl group which may be substituted with one group or more than one group selected from substituent group α; R2 is, for example, a C6-C10 aryl group which may be substituted with one group or more than one group selected from substituent group α; and X is, for example, a hydroxyl group or a C1-C6 alkoxy group].